Cannabidiol and palmitoylethanolamide are anti-inflammatory in the acutely inflamed human colon
Laboratory studyHumans
- Design
- Laboratory study
- Subjects
- Caco-2 cell cultures and human colon tissue explants from bowel cancer, inflammatory bowel disease and appendicitis resections
- Dose used in the study
- Palmitoylethanolamide or cannabidiol at 10 micromolar in culture, with an inflammatory stimulus
- Duration
- Tissue culture
- What was measured
- Nine intracellular signalling phosphoproteins, cytokine secretion, and receptor antagonist studies
What the authors reported
Palmitoylethanolamide reduced inflammatory signalling in cells and explants and prevented the rise in cytokine release in explant colon, an effect blocked by a PPAR-alpha antagonist. It was anti-inflammatory in both inflammatory bowel disease and appendicitis tissue.
Limits of this study
Tissue culture, not a treatment study. The cytokine effect appeared in explants but not in the cell line. The same group's later human permeability trial is Couch 2019. Independent academic group.
Source
PubMed 28954820 · doi:10.1042/CS20171288
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.